Salute e Benessere
LenioBio secures EUR 3.7M of EU4Health funding to develop ALiCE® for cost-effective and rapid production of protein-based medicines
This EU4Health action contributes to the European Union's strategic objective to strengthen the availability, accessibility, and affordability of essential medicines. By supporting the development of innovative manufacturing processes, HERA aims to enable more efficient, cost-effective, scalable, sustainable, and environmentally cleaner production of medicines.
LenioBio will contribute with a project titled " ", where key goals for the project include:
" said André Goerke, CEO of LenioBio.
LenioBio's project has been awarded the STEP Seal by the European Commission. The STEP Seal is granted to proposals deemed strategically important for Europe's technological and health sovereignty (https://www.leniobio.com/press-release/leniobio-earns-prestigious-eu-step-seal-a-signal-of-excellence-for-investors/).
ALiCE Cell-Free Protein Expression System is designed to scale seamlessly from research to production, enabling the rapid synthesis of complex proteins without relying on living cells. The platform is already supporting vaccine development and drug discovery by enabling fast, flexible protein production. With support from the EU4Health grant, LenioBio is now advancing ALiCE to meet the demands of clinical use and large-scale manufacturing.
LenioBio GmbH is a protein expression platform company committed to the advancement of transformative technology for the discovery, development, and large-scale production of proteins, unconstrained by the limitations of the cell. LenioBio was established as a legal entity in Germany in
September 2016 , with offices in Dusseldorf and R&D and production labs in Aachen. For more information about LenioBio, please visit our website at www.leniobio.com and follow LenioBio on LinkedIn.
The European Health and Digital Executive Agency (HaDEA) implements the vast majority of the EU4Health programme by managing calls for proposals and tenders from 2021 to 2027. The programme and its calls represent an ambitious response to the COVID-19 pandemic, but go beyond crisis response to address the resilience of European healthcare systems and contribute to a healthier Europe. EU4Health funds actions that include increasing the availability, accessibility, and affordability of medicines and medical products, boosting preparedness for cross-border health threats, and advancing innovation in healthcare. Learn more here (https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthier-european-union_en)
The European Commission's Health Emergency Preparedness and Response Authority (HERA) was established in response to lessons learned from the COVID-19 pandemic. HERA supports projects that strengthen the EU's capacity to prevent, detect, and respond to serious health emergencies, ensuring the timely availability of critical medical countermeasures. Learn more here (https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera_en)
Akanksha Ranjit
Marketing & Communications
LenioBio GmbH
a.ranjit@leniobio.com
Photo - https://mma.prnewswire.com/media/2735876/LenioBio_Health_Grant.jpg
Logo - https://mma.prnewswire.com/media/2735875/LenioBio_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/leniobio-secures-eur-3-7m-of-eu4health-funding-to-develop-alice-for-cost-effective-and-rapid-production-of-protein-based-medicines-302511105.html